News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
277,273 Results
Type
Article (14422)
Company Profile (101)
Press Release (262743)
Multimedia
Podcasts (69)
Webinars (14)
Section
Business (88352)
Career Advice (467)
Deals (15429)
Drug Delivery (81)
Drug Development (36758)
Employer Resources (50)
FDA (6409)
Job Trends (6242)
News (150862)
Policy (14137)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (448)
Accelerated approval (21)
Adcomms (9)
Allergies (91)
Alliances (23320)
ALS (68)
Alzheimer's disease (514)
Antibody-drug conjugate (ADC) (148)
Approvals (6695)
Artificial intelligence (255)
Autoimmune disease (73)
Automation (20)
Bankruptcy (151)
Best Places to Work (4371)
BIOSECURE Act (9)
Biosimilars (148)
Biotechnology (39)
Bladder cancer (51)
Brain cancer (39)
Breast cancer (200)
Cancer (1631)
Cardiovascular disease (192)
Career advice (421)
Career pathing (14)
CAR-T (61)
CDC (7)
Cell therapy (190)
Cervical cancer (16)
Clinical research (32444)
Collaboration (907)
Company closure (1)
Compensation (380)
Complete response letters (44)
COVID-19 (785)
CRISPR (52)
C-suite (604)
Cystic fibrosis (60)
Data (2380)
Decentralized trials (1)
Denatured (18)
Depression (58)
Dermatology (14)
Diabetes (148)
Diagnostics (1439)
Digital health (13)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (149)
Drug pricing (121)
Drug shortages (15)
Duchenne muscular dystrophy (95)
Earnings (34201)
Editorial (24)
Employer branding (4)
Employer resources (46)
Events (39675)
Executive appointments (595)
FDA (7759)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (524)
Gene editing (83)
Generative AI (24)
Gene therapy (199)
GLP-1 (480)
Government (1426)
Grass and pollen (4)
Guidances (171)
Healthcare (3611)
HIV (16)
Huntington's disease (10)
IgA nephropathy (48)
Immunology and inflammation (81)
Immuno-oncology (26)
Indications (91)
Infectious disease (875)
Inflammatory bowel disease (85)
Inflation Reduction Act (7)
Influenza (28)
Intellectual property (130)
Interviews (60)
IPO (5920)
IRA (33)
Job creations (2058)
Job search strategy (374)
JPM (29)
Kidney cancer (11)
Labor market (32)
Layoffs (208)
Leadership (10)
Legal (3450)
Liver cancer (24)
Longevity (9)
Lung cancer (220)
Lymphoma (147)
Machine learning (14)
Management (17)
Manufacturing (535)
MASH (87)
Medical device (1312)
Medtech (1326)
Mergers & acquisitions (10004)
Metabolic disorders (533)
mRNA (60)
Multiple sclerosis (59)
NASH (15)
Neurodegenerative disease (101)
Neuropsychiatric disorders (46)
Neuroscience (1021)
Neurotech (1)
NextGen: Class of 2026 (1589)
Non-profit (605)
Now hiring (22)
Obesity (276)
Opinion (151)
Ovarian cancer (63)
Pain (135)
Pancreatic cancer (68)
Parkinson's disease (101)
Partnered (11)
Patents (265)
Patient recruitment (162)
Peanut (15)
People (30141)
Pharmaceutical (60)
Pharmacy benefit managers (18)
Phase 1 (8408)
Phase 2 (13702)
Phase 3 (12377)
Pipeline (3256)
Policy (147)
Postmarket research (1402)
Preclinical (3396)
Press Release (25)
Prostate cancer (108)
Psychedelics (20)
Radiopharmaceuticals (152)
Rare diseases (445)
Real estate (2668)
Recruiting (19)
Regulatory (11308)
Reports (16)
Research institute (581)
Resumes & cover letters (56)
Rett syndrome (9)
RNA editing (8)
RSV (24)
Schizophrenia (86)
Series A (105)
Series B (60)
Service/supplier (2)
Sickle cell disease (54)
Special edition (11)
Spinal muscular atrophy (84)
Sponsored (11)
Startups (1651)
State (2)
Stomach cancer (6)
Supply chain (60)
Tariffs (71)
The Weekly (49)
Vaccines (261)
Venture capital (38)
Weight loss (164)
Women's health (47)
Worklife (4)
Date
Today (3)
Last 7 days (224)
Last 30 days (1099)
Last 365 days (10320)
2026 (4424)
2025 (10712)
2024 (12494)
2023 (14246)
2022 (19557)
2021 (20068)
2020 (19033)
2019 (14886)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11923)
2010 (10888)
Location
Africa (322)
Alabama (20)
Alaska (1)
Arizona (85)
Arkansas (4)
Asia (21155)
Australia (2729)
California (3806)
Canada (1744)
China (692)
Colorado (169)
Connecticut (152)
Delaware (159)
Europe (41513)
Florida (719)
Georgia (74)
Hawaii (1)
Idaho (10)
Illinois (436)
India (62)
Indiana (292)
Iowa (2)
Japan (320)
Kansas (82)
Kentucky (21)
Louisiana (6)
Maine (2)
Maryland (486)
Massachusetts (3063)
Michigan (53)
Minnesota (199)
Mississippi (1)
Missouri (37)
Montana (9)
Nebraska (8)
Nevada (19)
New Hampshire (9)
New Jersey (1678)
New Mexico (7)
New York (1093)
North Carolina (724)
North Dakota (2)
Northern California (1783)
Ohio (91)
Oklahoma (5)
Oregon (18)
Pennsylvania (835)
Puerto Rico (17)
Rhode Island (18)
South America (508)
South Carolina (11)
Southern California (1680)
Tennessee (64)
Texas (546)
United States (15081)
Utah (65)
Virginia (200)
Washington D.C. (42)
Washington State (277)
West Virginia (1)
Wisconsin (49)
Wyoming (1)
277,273 Results for "cantex pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER
Cantex Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex’ azeliragon, a well-tolerated once-a-day pill, for the treatment of pancreatic cancer.
May 20, 2024
·
3 min read
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING
Cantex Pharmaceuticals, Inc. announced today that Cantex’s azeliragon, a well-tolerated once-a-day pill that inhibits “RAGE” (the receptor for advanced glycation end products), will be featured in four abstracts at this year’s 2024 ASCO Annual Meeting to be held in Chicago.
May 28, 2024
·
3 min read
BioMidwest
Cantex Pharmaceuticals to Participate in the Bio CEO & Investor Conference
Cantex Pharmaceuticals, Inc. announced that Stephen Marcus, M.D., Chief Executive Officer, will participate in the BIO CEO & Investor Conference being held February 26-27, 2024 in New York City.
February 22, 2024
·
2 min read
CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT
Cantex Pharmaceuticals , Inc. announced today that the Company’s CEO, Stephen Marcus, M.D., will be an expert speaker at 5th Annual Glioblastoma Drug Development Summit, which will be held March 26-28 at the Hilton Boston Logan Airport.
March 19, 2024
·
4 min read
BioMidwest
Cantex Pharmaceuticals to Present at the Medinvest Oncology Investor Conference in Boston
Cantex Pharmaceuticals, Inc. announced that it will present at the MedInvest Oncology Investor Conference being held June 21-22, 2023, in Boston, MA.
June 15, 2023
·
2 min read
Drug Development
Cantex Pharmaceuticals Announces Initiation of an Investigator-Initiated Phase 2 Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases
Cantex Pharmaceuticals, Inc. announced today the initiation of a Phase 2 clinical trial to assess the safety and effectiveness of Cantex’s azeliragon combined with stereotactic radiosurgery in patients with brain metastases.
August 28, 2023
·
4 min read
CANTEX PHARMACEUTICALS ANNOUNCES ISSUANCE OF A PATENT FOR AZELIRAGON AS A TREATMENT OF GLIOBLASTOMA
Cantex Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office has issued U.S. Patent No. 11,648,235, titled “Treatment of Glioblastoma,” with claims to a method of treating glioblastoma with azeliragon.
May 16, 2023
·
2 min read
Drug Development
CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA
Cantex Pharmaceuticals, Inc. and Lenox Hill Hospital’s Department of Neurological Surgery announced the initiation of a Phase 2 study to assess the safety and effectiveness of azeliragon in combination with radiation therapy as a treatment for newly diagnosed unmethylated glioblastoma.
September 18, 2023
·
4 min read
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA
Cantex Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex’ azeliragon, a well-tolerated once-a-day pill, for the treatment of glioblastoma.
January 9, 2023
·
2 min read
Drug Development
CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL
Cantex Pharmaceuticals, Inc. announced today the initiation of a randomized, double-blind, placebo-controlled, multicenter, Phase 3 pivotal clinical trial.
September 27, 2023
·
4 min read
1 of 27,728
Next
